NEUROVITA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,051,823 | 1,547,510 | 1,513,164 | 2,047,542 | 1,547,169 | 2,095,398 | 1,975,385 | 1,962,463 |
| Profit before tax | 28,441 | 75,891 | 100,902 | 182,703 | 41,124 | 189,423 | 99,853 | 82,017 |
| Net profit | 23,768 | 62,830 | 85,496 | 161,860 | 34,903 | 159,731 | 84,710 | 69,091 |
| Equity | 182,024 | 210,854 | 236,350 | 268,210 | 303,113 | 412,844 | 386,879 | 413,970 |
| Liabilities | 160,522 | 294,281 | 383,508 | 728,455 | 429,034 | 365,720 | 411,628 | 352,796 |
| Non-current assets | 32,907 | 107,648 | 112,669 | 122,383 | 95,170 | 128,574 | 140,649 | 142,159 |
| Current assets | 309,639 | 409,614 | 507,438 | 876,226 | 638,002 | 650,730 | 654,358 | 619,621 |
| Total assets | 342,546 | 517,262 | 620,107 | 998,609 | 733,172 | 779,304 | 795,007 | 761,780 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 381,501 | 396,189 | 422,726 |
| Social insurance contributions | - | - | - | - | - | 68,372 | 83,029 | 88,181 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -20.0% | +47.1% | -2.2% | +35.3% | -24.4% | +35.4% | -5.7% | -0.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 6.9% | 12.1% | 13.8% | 16.2% | 4.8% | 20.5% | 10.7% | 9.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 13.1% | 29.8% | 36.2% | 60.3% | 11.5% | 38.7% | 21.9% | 16.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.3% | 4.1% | 5.7% | 7.9% | 2.3% | 7.6% | 4.3% | 3.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 2.7% | 4.9% | 6.7% | 8.9% | 2.7% | 9.0% | 5.1% | 4.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.9 | 1.4 | 1.6 | 2.7 | 1.4 | 0.9 | 1.1 | 0.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 106,066 | 167,298 | 160,689 | 208,225 | 148,528 | 207,809 | 169,318 | 165,842 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
NEUROVITA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-11-18 | 2024-11-20 | 0.02 |
| 2024-10-24 | 2024-11-13 | 0.02 |
| 2024-07-16 | 2024-07-16 | 32.44 |
| 2023-10-17 | 2023-10-26 | 45.14 |
| 2022-09-16 | 2022-09-21 | 483.42 |
| 2022-07-25 | 2022-08-01 | 3.42 |
| 2022-06-16 | 2022-06-26 | 909.35 |
| 2022-04-19 | 2022-05-11 | 18.49 |
NEUROVITA - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
NEUROVITA, UAB (company code 110791756) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €1.96M and net profit of €69.1K, with a profit margin of 3.5%. Results softened further from 2024, when revenue was €1.98M and net profit €84.7K, and from 2023, when revenue reached €2.10M and net profit €159.7K. This shows a gradual decline in both sales and profitability over the three-year period. The balance sheet remained stable, with total assets of €761.8K in 2025, equity of €414.0K and liabilities of €352.8K. Equity represented 54.3% of assets, while debt-to-equity stood at 0.85. Efficiency indicators were solid, with asset turnover at 2.58x, ROE at 16.7% and ROA at 9.1%. Revenue per employee was €178.4K and profit per employee €6.3K, indicating moderate productivity despite the lower profit level.